Free Trial

Penumbra (PEN) Stock Price, News & Analysis

-8.33 (-4.19%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
247,576 shs
Average Volume
333,463 shs
Market Capitalization
$7.39 billion
P/E Ratio
Dividend Yield
Price Target

Penumbra MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
57.7% Upside
$300.64 Price Target
Short Interest
5.49% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.64mentions of Penumbra in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$5.51 M Sold Last Quarter
Proj. Earnings Growth
From $2.87 to $3.92 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.53 out of 5 stars

Medical Sector

37th out of 915 stocks

Surgical & Medical Instruments Industry

8th out of 91 stocks

PEN stock logo

About Penumbra Stock (NYSE:PEN)

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN Stock Price History

PEN Stock News Headlines

Penumbra, Inc. (PEN)
J.P. Morgan Reaffirms Their Hold Rating on Penumbra (PEN)
The Latest Analyst Ratings For Penumbra
Penumbra Q1 2024 Earnings Preview
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$90.95 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$2.69 per share
Book Value
$31.05 per share


Free Float
Market Cap
$7.39 billion
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

PEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price target for 2024?

10 equities research analysts have issued 12-month target prices for Penumbra's shares. Their PEN share price targets range from $240.00 to $376.00. On average, they expect the company's share price to reach $300.64 in the next twelve months. This suggests a possible upside of 57.7% from the stock's current price.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How have PEN shares performed in 2024?

Penumbra's stock was trading at $251.54 at the beginning of 2024. Since then, PEN stock has decreased by 24.2% and is now trading at $190.64.
View the best growth stocks for 2024 here

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our PEN earnings forecast

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) announced its quarterly earnings results on Tuesday, May, 7th. The company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.42 by $0.01. The company earned $278.70 million during the quarter, compared to the consensus estimate of $274.94 million. Penumbra had a trailing twelve-month return on equity of 7.83% and a net margin of 8.52%. Penumbra's revenue was up 15.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.23 EPS.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.52%), Price T Rowe Associates Inc. MD (7.81%), Capital Research Global Investors (2.92%), Champlain Investment Partners LLC (2.80%), William Blair Investment Management LLC (2.15%) and Clearbridge Investments LLC (2.03%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PEN) was last updated on 5/24/2024 by Staff

From Our Partners